Table 4

Total cumulative dosing and treatment duration

Safety population

AC-1202

n = 86

Placebo

n = 66


Total Cumulative Dose

Mean dose (grams) ± SD

3555.00 ± 1883.89

4424.55 ± 1326.78

Median

4515

4965

Median percent of intended dose

86.99%

95.66%

(Range)

(30, 5460)

(150, 5550)


Treatment Duration (days)

N*

82

66

Mean ± SD

71.66 ± 31.08

83.91 ± 18.26

Median

90.0

91.0

(Range)

(1, 101)

(5, 103)


Genotyped population

APOE4(-)

n = 36

APOE4(+)

n = 39

APOE4(-)

n = 27

APOE4(+)

n = 33


Total Cumulative Dose

Mean dose (grams)

3049.17

4015.38

4382.22

4375.45

± SD

± 2076.41

± 1531.93

1398.93

± 1386.91

Median

3780

4740

4950

4980

Median percent of intended dose

72.8%

91.3%

95.4%

95.6%

Range (grams)

30 – 5430

30 – 5460

240 – 5490

150 – 5550


Treatment Duration (days)

N*

34

38

27

33

Mean

64.1

77.8

87.1

80.3

± SD

± 36.44

± 24.3

± 11.2

+23.3

Median

88.0

90.0

91.0

91.0

Range (days)

3 – 96

1 – 101

56 – 103

5 – 100


*Treatment duration was unknown for 4 AC-1202 subjects for whom last date of study medication was not recorded

Henderson et al. Nutrition & Metabolism 2009 6:31   doi:10.1186/1743-7075-6-31

Open Data